Volition appoints pharmaventures for capture pcr™ and oncology portfolio licensing

Henderson, nev. , july 9, 2024 /prnewswire/ -- volitionrx limited (nyse american: vnrx) ("volition"), a multi-national epigenetics company, has appointed pharmaventures ltd ("pharmaventures"), a leading transaction advisory firm, to provide strategic advice and transactional support on the out-license of volition's expanding oncology portfolio.
VNRX Ratings Summary
VNRX Quant Ranking